Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus ULTRAVIST 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus ULTRAVIST 370.
CONRAY 43 vs ULTRAVIST 370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Iodinated non-ionic contrast agent that attenuates X-rays due to its high iodine content (370 mg I/mL), enhancing vascular and tissue contrast during imaging. Does not bind to plasma proteins and has minimal pharmacological effects.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Adult: IV administration of 370 mg iodine/mL at 1-1.5 mL/kg (370-555 mg I/kg) for CT; up to 300 mL total. Rate: 1-5 mL/sec.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 2 hours (normal renal function); prolonged to up to 36 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Renal: 95% unchanged within 24 hours via glomerular filtration; Biliary/Fecal: <5%; negligible biliary excretion.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent